CoviCept Therapeutics has received a $2.3M seed investment from Forbion.

CoviCept Therapeutics is a newly founded company based in San Diego, focused on the development of a small molecule that inhibits the replication and spread of RNA viruses, including SARS-Cov-2. CoviCept is developing a small molecule that targets a host protein that is critical for RNA viral replication and that has shown efficacy in a preclinical model of SARS-CoV-2 infection, and in cell cultures infected with various RNA viruses including Zika and Dengue. The lead molecule has shown good tolerability, availability and biodistribution in humans.